Mostra 1 - 6 risultati di 6 ricerca 'on behalf of the Collaborative Group', tempo di risposta: 0,03s
Raffina i risultati
-
1
Cellular Immune Response to BNT162b2 mRNA COVID-19 Vaccine in a Large Cohort of Healthcare Workers in a Tertiary Care University Hospital di Cristina Costa, Gitana Scozzari, Enrica Migliore, Claudia Galassi, Giovannino Ciccone, Guido Ricciardelli, Antonio Scarmozzino, Lorenzo Angelone, Paola Cassoni, Rossana Cavallo, on behalf of the Collaborative Group
Pubblicazione 2022-06-01
Articolo -
2
Factors Influencing Level and Persistence of Anti SARS-CoV-2 IgG after BNT162b2 Vaccine: Evidence from a Large Cohort of Healthcare Workers di Cristina Costa, Enrica Migliore, Claudia Galassi, Gitana Scozzari, Giovannino Ciccone, Maurizio Coggiola, Enrico Pira, Antonio Scarmozzino, Giovanni La Valle, Paola Cassoni, Rossana Cavallo, on behalf of the Collaborative Group
Pubblicazione 2022-03-01
Articolo -
3
Is global cardiovascular risk considered in current practice? Treatment and control of hypertension, hyperlipidemia, and diabetes according to patients’ risk level di Daria Roccatagliata, Fausto Avanzini, Lara Monesi, Vittorio Caimi, Davide Lauri, Paolo Longoni, Roberto Marchioli, Massimo Tombesi, Gianni Tognoni, Maria Carla Roncaglioni, on behalf of the Collaborative Group Risk, Prevention Study
Pubblicazione 2006-12-01
Articolo -
4
How I curate: applying American Society of Hematology-Clinical Genome Resource Myeloid Malignancy Variant Curation Expert Panel rules for RUNX1 variant curation for germline predis... di David Wu, Xi Luo, Simone Feurstein, Chimene Kesserwan, Shruthi Mohan, Daniel E. Pineda-Alvarez, Lucy A. Godley, on behalf of the collaborative group of the American Society of Hematology - Clinical Genome Resource Myeloid Malignancy Variant Curation Expert Panel
Pubblicazione 2020-04-01
Articolo -
5
CRADLE-5: a stepped-wedge type 2 hybrid implementation-effectiveness cluster randomised controlled trial to evaluate the real-world scale-up of the CRADLE Vital Signs Alert interve... di Alexandra E. Ridout, Francis L. Moses, Simren Herm-Singh, Cristina Fernandez Turienzo, Paul T. Seed, Venetia Goodhart, Nicola Vousden, Betty Sam, Mariama Momoh, Daniel Kamara, Katy Kuhrt, Sorie Samura, Candace Beoku-Betts, Alice Hurrell, Kate Bramham, Sartie Kenneh, Francis Smart, Lucy Chappell, Jane Sandall, Andrew Shennan, on behalf of CRIBS Collaborative Group
Pubblicazione 2023-09-01
Articolo -
6
Impact of synthetic and biological immunomodulatory therapy on the duration of 17DD yellow fever vaccine-induced immunity in rheumatoid arthritis di Clarissa de Castro Ferreira, Ana Carolina Campi-Azevedo, Vanessa Peruhype-Magalhāes, Jordana Grazziela Coelho-dos-Reis, Lis Ribeiro do Valle Antonelli, Karen Torres, Larissa Chaves Freire, Ismael Artur da Costa-Rocha, Ana Cristina Vanderley Oliveira, Maria de Lourdes de Sousa Maia, Sheila Maria Barbosa de Lima, Carla Magda Domingues, Andréa Teixeira-Carvalho, Olindo Assis Martins-Filho, Lícia Maria Henrique da Mota, on behalf of the Collaborative Group for Studies of Yellow Fever Vaccine
Pubblicazione 2019-03-01
Articolo